Shanghai Junshi Biosciences Co., Ltd. (688180.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 32.75

From 52W high−13.84%

Volume11.30M

Market capCNY 35.78B

P/E (TTM)−40.9x

P/S (TTM)12.6x

Div yield—

Key dataSep 18, 2026

Open

CNY 32.75

From 52W high

−13.84%

Volume

11.30M

Market cap

CNY 35.78B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−48.7x

P/E (TTM)

−40.9x

RSI (14)

46.4

MomentumView details →

1D Return

−6.87%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−40.9x

EV/EBITDA

−48.7x

EV/Sales

12.8x

P/S (TTM)

12.6x

P/B (TTM)

6.1x

ProfitabilityView details →

Gross Margin

80.93%

Net Margin

−24.26%

EBITDA Margin

−26.26%

ROE (TTM)

−11.21%

ROA (TTM)

−4.67%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

+31.72%

EPS YoY

+46.95%

FCF YoY

+24.69%

Revenue CAGR 3Y

+19.79%

EPS CAGR 3Y

+33.08%

EBITDA YoY

—

MomentumView details →

1D Return

−6.87%

YTD Return

—

1Y Return

—

RSI (14)

46.4

vs 50D SMA

−7.03%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.74x

Current Ratio

2.14x

Quick Ratio

1.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

CNY 0.04

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.02B

Net Income (TTM)

−441.00M

Op. CF (TTM)

−236.42M

Next earningsOct 23, 2026 →

Latest newsMore news →

Shanghai Junshi Biosciences held an online investor briefing on its 2026 half-year results on September 14, 2026, with CEO Zou Jianjun, independent non-executive director Li Zhongxian, CFO Xu Baohong and board secretary Wang Zhengyu receiving investors.6d ago

Junshi Biosciences announced at its 2026 interim results briefing that Phase III clinical trials for its drug candidates JS203 and JS207 are expected to start within 2026.7d ago

Similar companies

IMBdx461030.KQ 万泰生物603392.SH 3SBio Inc.01530.HK 三生国健688336.SH Shanghai Henlius Biotech, Inc.02696.HK Oncocross Co., Ltd.382150.KQ Find similar companies →

Latest newsMore news →

Shanghai Junshi Biosciences held an online investor briefing on its 2026 half-year results on September 14, 2026, with CEO Zou Jianjun, independent non-executive director Li Zhongxian, CFO Xu Baohong and board secretary Wang Zhengyu receiving investors.6d ago Junshi Biosciences announced at its 2026 interim results briefing that Phase III clinical trials for its drug candidates JS203 and JS207 are expected to start within 2026.7d ago Junshi Biosciences announced the cancellation of 6.3 million H shares repurchased between May 26 and June 4, 2026, at a price of HK$17.51 per share, reducing total issued shares to 327,888,000.20d ago